• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo

by MM360 Staff | May 6, 2025 | Uncategorized

Source: CureToday articles The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas. Read More

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

by MM360 Staff | May 6, 2025 | Uncategorized

Source: CureToday articles Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation. Read More

A Staunch Advocate For Radiation Oncology Nursing and Compassionate Care

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles Everyone knows someone who has been affected by cancer. Read More

A Personalized Approach to Bladder Preservation in Urologic Cancers

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan. Read More

Mitigating Peripheral Neuropathy During Cancer Treatment

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles Dr. Shirley D’Sa discusses the importance of catching peripheral neuropathy in patients with Waldenstrom macroglobulinemia early on, and how to treat it. Read More

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis. Read More
« Older Entries

Recent Content

  • Expert: Understanding OTC Allergy Medications and Symptom Management
  • One Dose of the HPV Vaccine Is over 97% Effective at Preventing HPV Infection
  • First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
  • Psilocybin at the Crossroads: Regulatory Barriers and the Pharmacist’s Role in Palliative Innovation
  • Study Demonstrates Semaglutide Improves Liver Histologic Results in Patients With MASH
  • Transforming What Community Pharmacy Offers: Giant Food’s Cancer Screening Initiative
  • Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines
  • Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
  • Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC
  • Rite Aid Intends to File Second Bankruptcy, Raising Questions About Its Future
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT